8月26日 - ** 药物开发商Marker Therapeutics MRKR.O股价盘前上涨29%，报1.63美元
** 该公司报告了其正在进行的早期试验 (link) 的数据，该试验对复发 B 细胞淋巴瘤（一种治疗后复发的血癌）患者的实验性疗法 MT-601 进行了测试。
** 公司称，66%的患者癌症缩小或消失，50%的患者在治疗后检测不到癌症
** 公司称，这种疗法没有严重的副作用
** 截至上一交易日收盘，股价累计下跌 60
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.